Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open-label study of the long term tolerability and safety of atomoxetine in treating the inattention, impulsivity and hyperactivity in children with fetal-alcohol syndrome or effects

Next Previous
Search
Trial Profile

An open-label study of the long term tolerability and safety of atomoxetine in treating the inattention, impulsivity and hyperactivity in children with fetal-alcohol syndrome or effects

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 05 Jul 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atomoxetine (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Adverse reactions

Most Recent Events

  • 02 Jun 2017 Status changed from recruiting to completed.
  • 20 May 2010 Planned end date changed from 1 Dec 2009 to 1 Jun 2009 as reported by ClinicalTrials.gov.
  • 27 Jul 2009 Planned end date changed from 1 Dec 2008 to 1 Dec 2009 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top